

## **Supplementary Materials:**



**Figure S1.** (**A**) Western blot analysis of CXCL12, CXCR4, phosphorylation smad3 (P-smad3), TGFR1, TGFR2 and phosphorylation mTOR (P-mTOR) in 4T1 cells pretreated with KR62436 (50  $\mu$ mol/L) for 48 h and then treated with or without DOX (0.425  $\mu$ mol/L) in the presence or absence of AMD3100 (30  $\mu$ mol/L) for another 48 h. (**B**) Western blot analysis of phosphorylation smad3 (P-smad3), TGFR1 and TGFR2 in 4T1 cells in 4T1 cells pretreated with KR62436 (50  $\mu$ mol/L) for 48 h and then treated with or without DOX (0.425  $\mu$ mol/L) in the presence or absence of rapamycin (1  $\mu$ mol/L) for another 48 h. All densitometric analysis of CXCL12, CXCR4, TGFR1 and TGFR2 protein expression relative to b-actin levels, P-smad3 protein expression relative to smad3 levels and P-mTOR protein expression relative to mTOR (n = 3, per group) were performed by using ImageJ.



**Figure S2.** Immunofluorescence analysis of MRP1 expression in the primary tumors. For each group, representative images of six different fields of view at  $200 \times$  magnification were evaluated. The scale bar indicated 50  $\mu$ m each panel.